

# SmartPA Criteria Proposal

<b>Drug/Drug Class:</b>	Electrolyte Depleters, Phosphate Lowering Agents PDL Edit
<b>First Implementation Date:</b>	January 14, 2009
<b>Proposed Date:</b>	June 18, 2020
<b>Prepared For:</b>	MO HealthNet
<b>Prepared By:</b>	MO HealthNet/Conduent
<b>Criteria Status:</b>	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

## Executive Summary

**Purpose:** The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

**Why Issue Selected:** Chronic kidney disease occurs in approximately 20 million Americans. One of the complications of this disease is hyperphosphatemia. As the kidney loses function, its ability to eliminate phosphorus declines, which results in hyperphosphatemia. Phosphorus is responsible for growth, maintenance, and repair of body tissues, and along with calcium, prevents bone-related disorders. Phosphorus is commonly found in foods such as milk, red meat, fish, poultry, eggs, and peanuts. Due to continuous dietary intake, unfortunately, dialysis alone does not maintain normal phosphorus levels in the blood for end stage renal disease participants. Phosphate-binding agents decrease phosphorus absorption from the gastrointestinal tract by binding dietary phosphorus. Calcium containing salts not only maintain positive calcium balance but also bind phosphorus. In the event of hypocalcemia, calcium supplementation or vitamin D may be necessary to slow or prevent bone disease. Non-calcium based phosphate binders are now available and are an alternative to calcium when hypercalcemia is present.

Total program savings for the PDL classes will be regularly reviewed.

**Program-Specific Information:**

Preferred Agents	Non-Preferred Agents
<ul style="list-style-type: none"> <li>• Calcium Acetate Caps</li> <li>• Sevelamer Carbonate Tabs (gen Renvela®)</li> </ul>	<ul style="list-style-type: none"> <li>• Auryxia™</li> <li>• Calcium Acetate Tabs OTC/Rx</li> <li>• Calphron®</li> <li>• Fosrenol®</li> <li>• Lanthanum Carbonate</li> <li>• Phoslyra®</li> <li>• Renagel®</li> <li>• Renvela®</li> <li>• Sevelamer Hydrochloride (gen Renagel®)</li> <li>• Sevelamer Pwd Pack</li> <li>• Velphoro®</li> </ul>

Type of Criteria:  Increased risk of ADE  
 Appropriate Indications

Preferred Drug List  
 Clinical Edit

Data Sources:  Only Administrative Databases

Databases + Prescriber-Supplied

## Setting & Population

- Drug class for review: Electrolyte Depleters, Phosphate Lowering Agents
- Age range: All appropriate MO HealthNet participants

## Approval Criteria

- Documented compliance on current therapy regimen **OR**
- Failure to achieve desired therapeutic outcomes with trial on 2 or more preferred agents
  - Documented trial period for preferred agents **OR**
  - Documented ADE/ADR to preferred agents

## Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if no approval criteria are met

## Required Documentation

Laboratory Results:   
MedWatch Form:

Progress Notes:   
Other:

## Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)  
Rule Type: PDL

## Default Approval Period

1 year

## References

1. Evidence-Based Medicine and Fiscal Analysis: "Phosphate Lowering Agents – Therapeutic Class Review", Conduent Business Services, L.L.C., Richmond, VA; April 2020.
2. Evidence-Based Medicine Analysis: "Phosphate Binders", UMKC-DIC; April 2020.
3. Lippincott, Williams, Wilkins. PDR Electronic Library, Montvale NJ; 2020.
4. USPDI, Micromedex; 2020.
5. Facts and Comparisons eAnswers (online); 2020 Clinical Drug Information, LLC.

### SmartPA PDL Proposal Form

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.